Press release<< Back
Mylan Launches Generic Pristiq® Tablets
Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, had
Currently, Mylan has 241 ANDAs pending
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.
(1) Antidepressants can increase the risk of suicidal thinking and behavior in children, adolescents and young adults. Monitor for worsening and emergence of suicidal thoughts and behaviors. This medicine is not approved for use in pediatric patients.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-pristiq-tablets-300421739.html
News Provided by Acquire Media